Reviva Pharmaceuticals Holdings, Inc.
RVPH
$0.6958
-$0.0242-3.36%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -2.77% | 25.18% | -6.44% | -5.73% | 20.54% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 51.76% | 105.04% | 73.72% | 282.20% | -126.90% |
| Change in Net Operating Assets | 23.11% | -188.51% | 596.59% | 81.57% | -2,812.97% |
| Cash from Operations | 9.96% | -114.56% | 49.96% | 27.71% | -32.10% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -100.00% | -- |
| Total Debt Repaid | -25.21% | -50.04% | 0.00% | -50.00% | 62.70% |
| Issuance of Common Stock | -98.55% | 344.21% | 33.56% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.96% | 369.84% | 35.12% | 707.44% | -98.78% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -203.40% | 1,378.25% | 89.31% | 49.13% | -161.94% |